The present study was carried out to compare the neuroprotective effect of the novel noncompetitive NMDA antagonist, FRl15427, with that of ( + )MK-SOI in rat focal cerebral ischemia. Focal cerebral ischemia was produced by permanent occlusion of the left middle ce rebral artery (MCA). Drugs were administered intraperi toneally immediately after ischemia and once a day for 6 successive days. FR115427 (10 mg/kg, i.p.) significantly improved neurologic deficit at I day after ischemia and
Focal cerebral ischemia induced by middle cere bral artery (MCA) occlusion in animals is the most relevant model of human stroke presently available (Graham., 1988) This experimental model in rats, first described by Tamura et al. (1981) , is widely used to determine the neuroprotective potential of drugs. In the rat MCA-occlusion model, N-methyl D-aspartate (NMDA) antagonists such as (+) 5-methyl-l 0, II-dihydro-5H-dibenzo[a,d]cyclohep ten-5, 1O-imine[( + ) have been shown to be potent neuroprotective agents (Dirnagl et a!., 1990; Gill et aI., 1992; Roussel et aI., 1992) .
Recently, it has been shown that FR115427 [( +) -1-methyl-l-phenyl-l ,2,3 ,4,-tetrahydroisoquinoline hydrochloride] is a potent noncompetitive NMDA antagonist (Hodgkiss et a!., 1993) . FR1 15427 inhib-reduced total infarct volume (54%) at 7 days after isch emia. Although FRl15427 (10 mg/kg, s.c.) produced neu ronal vacuolization similar to ( + )MK -SO 1, FR 115427 did not produce adverse effects such as a loss of body weight, mortality, and hypothermia, in contrast to (+ )MK-SOI.
These results suggest that FRl15427 may be useful in the treatment of stroke. Key Words: Focal ischemia Neuroprotection-Noncompetitive NMDA antagonist FRl15427-Rats.
ited the binding of eH]MK-801 to rat cortical syn aptosomal membranes and was 14-fold less potent than ( + )MK-801. In addition, the neuroprotective effect of FR-115427 in the gerbil global brain isch emia model has been demonstrated (Nakanishi et aI., 1994) . The present study was designed to deter mine whether repeated administration of FR115427 has neuroprotective effect in the focal cerebral isch emia model, and to compare its effect with that of (+ )MK-801.
METHODS
Experimental procedures were performed under the guidelines of the Animal Experimental Committee of Fu jisawa Pharmaceutical Co., Ltd. The experiments were carried out using adult male Sprague-Dawley rats, weigh ing 300-400 g (SLC, Japan). The animals were anesthe tized with 2% halothane in a mixture of 70% nitrous ox ide:30% oxygen delivered through a close fitting face mask during surgery. The proximal portion of the MCA was occluded according to the method established by Tamura (19S1) . Body temperature was monitored using a rectal thermometer (CTM-303, TERUMO, Tokyo, Japan) and the animals were maintained at 37.0-3S.0°C using an external heating lamp during and after surgery. Drugs were administered intraperitoneally at doses of 0.1, 1.0, and 10.0 mg/kg immediately after MCA occlusion, and were then administered once daily over the following 6 days until a day before killing. In separate experiments, physiologic variables were measured before and 24 h after MCA occlusion. Twenty-four hours after MCA occlu sion, the neurologic status of the rats were assessed. The rating scales for neurologic deficit were used in accor dance with the method of Bederson et al. (1986) .
Seven days after MCA occlusion, the brains were per fusion-fixed with 300 ml of 4% formaldehyde in 0.1 M phosphate-buffer (pH 7.4) under 110 mm Hg pressure, embedded in paraffin wax, and 4-5-l-lm sections obtained. These sections were stained either with hematoxylin eosin or with a combination of cresyl violet and luxol fast blue and were examined by light microscopy. The areas of ischemic damage were delineated at six preselected coronal levels from anterior 3.5 mm to anterior 13.5 mm under microscopic observation, and the extent of isch emic damage was determined from photographs using a digitizer (KD-4300, GRAPHTEC, Tokyo, Japan). Each section was identified by reference to corresponding lev els in an atlas of the rat brain. The infarct volumes of total hemispheres and cortex were expressed in absolute terms (mm3).
In order to examine the neuropathologic changes (vac uole formation) in the brain induced by NMDA antago nists, FRl15427 (3.2, 10, and 32 mg/kg), (+ )MK-801 (0.32, 1.0, and 3.2 mg/kg) and CGS19755 [cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid] (100 mg/ kg) were injected subcutaneously into rats. Four hours after administration of the drugs, the rats were killed and the brain sections, stained with hematoxylin-eosin, were observed by light microscopy. FR 115427, (+ )MK -801, and CGS19755 were synthesized in the Chemistry De partment, New Drug Research Laboratoies, Fujisawa Pharmaceutical Co. Ltd (Osaka, Japan).
All data were analyzed using Dunnett's t test. Values of p < 0.05 were considered to be significant, and results were expressed as mean ± SD.
RESULTS
There was no significant difference in any phys iologic variables of the saline-treated control or FRl1 5427-treated groups, either before or after MCA occlusion (Table 1) . In contrast, the decrease in rectal temperature induced by high doses of ( + )MK-801 (10.0 mg/kg) compared with the control group was significant 24 h after MCA occlusion, as was the decrease in pH (Table 1) .
There was a decrease in body weight to a similar extent in both the control and FRl15427-treated groups. In contrast, (+ )MK-801 (10 mg/kg) mark edly reduced body weight, and mortality rates dur ing 1 week after surgery were 0% (0.1 mg/kg), 22% (1.0 mg/kg) and 30% (10.0 mg/kg). Therefore, dead animals were excluded from the data.
In FR1 1 5427 (10 mg/kg) and (+ )MK-801 (1 .0 and 10 mg/kg)-treated animals, significant improve ments in the neurologic deficit were observed 24 h after MCA occlusion compared with the control group (Fig. 1) .
The high dose of FR1 1 5427 (1 0.0 mg/kg) signifi cantly reduced the volume of infarction compared with controls by 54% ( Fig. 2A ). (+ )MK-801 (1.0 and 10.0 mg/kg) also significantly reduced the vol ume of infarction compared with controls by 52% at 1 mg/kg (Fig. 2B ). Furthermore, all drugs [FR11 5427, (+ )MK-801 , and CGS1 9755] caused vacuolization of the cytoplasm in the cingulate retrosplenial neurons (Table 2) .
DISCUSSION
The present study demonstrated that systemic administration of the noncompetitive NMDA antag onists, FR1 1 5427 and (+ )MK-801 , reduces the ex tent of ischemic brain damage. The effective dose of FR1 1 5427 (10 mg/kg, i.p.) was 10 times higher than that of ( + )MK-801 (1 mg/kg, i.p.) in the rat MCA occlusion model. Recently, it has been reported that the K; value for FR115427 is 14 times higher Each bar is mean ± SO.
than that of (+ )MK-801 in the eH]MK-801 binding assay using rat cortical synaptosomal membranes (Hodgkiss et aI., 1993) . In addition, the anticonvul sive dose of (+ )MK-801 (3.2 mg/kg, i.p.) for NMDA-induced seizures in mice is 10 times less than FRl15427 (32 mg/kg, i.p.) (data not shown). Thus the difference in potency between FRl15427 and (+ )MK-801 in the MCA occlusion model is consistent with their activities as NMDA antago nists both in vitro and in vivo. These results strongly suggest that the neuroprotective effect of FR115427 is due to NMDA receptor blockade. In the present experiments, rectal temperature was maintained normothermic by means of a heat ing lamp during MCA occlusion surgery. In sepa rate experiments, the FRl15427-treated group showed no difference in rectal temperature com pared with the control group at 24 h after occlusion (Table 1 ). It is known that the change in brain tem perature in awakening animals subjected to focal cerebral ischemia parallels the rectal temperature (Xue et aI., 1992) . Therefore, the neuroprotective effect of FR1l5427 is unlikely to be due to hypo thermia. In contrast, rectal temperatures decreased 24 h after ischemia in (+ )MK-801 (10 mg/kg) treated animals (Table 1 ). It is possible that post ischemic hypothermia produced by (+ )MK-801 contributes to the neuroprotective activity in the focal cerebral ischemia model. Furthermore, FRl15427-treated rats showed no difference in physiologic variables such as P a02 and Paco2 (data not shown), body weight gain, or mor tality rate when compared with the control group. However, repeated administration of( + )MK-801 at the minimal effective dose (1 mg/kg, i.p.) produced a remarkable loss of body weight and significant mortality. Values are the number of animals in which cingulateretrosplenial vacuolization occurs. Adult male Sprague-Dawley rats (297-325 g) were injected subcutaneously with NMDA antagonists and were killed 4 h later for histopathologic evaluation of the brain by light microscopy. All compounds caused vacuolization of neuronal cytoplasm in cingulate-retrosplenial neurons.
It has been reported that NMDA antagonists gen erally have relatively low therapeutic indexes, and behavioral side effects and possible neuronal dam age have raised concerns regarding their clinical utility. For example, competitive and noncompeti tive NMDA antagonists have been reported to cause neuropathologic changes such as vacuole for mation in rat brains (Olney et aI., 1989; Fix et aI., 1993) , although vacuolization of neuronal cyto plasm in the cingulate cortex after a single treat ment with ( + )MK-801 is limited to an acute time interval (Olney et aI., 1989) .
In the present experiments, we observed the same pathologic changes in the posterior cingulate cortex regions of rats treated with FR1 1 5427, (+)MK-801, and CGS1 97 55. The effect of FR1 1 5427 was >30 times less potent than that of ( + )MK-801 (Table 2 ). The neurotoxic action of ( + )MK-801 in the adult rat cingulate cortex is abol ished by coadministration of scopolamine, a cholin ergic muscarinic antagonist, whereas pretreatment with pilocarpine potentiates the vacuolization by (+ )MK-801 (Olney et aI., 1991 ) . In preliminary ex periments we have confirmed that both FR1 1 5427 and ( + )MK-80l inhibit carbachol-induced contrac tions at the micromolar range in the guinea pig il eum (Katsuta et aI., personal communication). These results suggest that both drugs have moder ate affinity for the muscarinic receptor and have antimuscarinic activity. Vacuolization produced by FR1l5427 might therefore be attenuated by the moderate antimuscarinic activity because J Cereb Blood Flow Metab, Vol. 15, No.2, 1995 FR1 1 5427 is about ten times less potent than (+ )MK-801 as an NMDA antagonist, whereas both drugs have similar potency for antimuscarinic ac tivity.
In conclusion, repeated administration of either FR1 1 5427 or (+ )MK-801 reduced cerebral infarct volume at 7 days after ischemia in the rat MCA occlusion model. However, FR115427 did not pro duce a loss of body weight or increased mortality as found with (+ )MK-801.
